GlassScriptPhysician profile
Kathryn C Bernhardt
NPI 1295233799
$9,256.00
in general payments reported to CMS, 2019-2025
35 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,897 · 2022: $2,559 · 2023: $1,321 · 2024: $1,966 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,611 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,611.14 |
| Education | $188.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $879.54 | 2021-2025 | |
| Janssen Biotech, INC. | $852.09 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $818.27 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Sun Pharmaceutical Industries INC. | $767.48 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $676.84 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $641.61 | 2021-2024 | Opzelura |
| Genzyme Corporation | $443.33 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $424.82 | 2023-2024 | Zoryve |
| Leo Pharma INC. | $395.82 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $334.62 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $319.39 | 2021-2024 | Cabtreo, Jublia |
| Novartis Pharmaceuticals Corporation | $298.12 | 2021-2023 | |
| Journey Medical Corporation | $263.96 | 2021-2022 | |
| Amgen INC. | $244.41 | 2021-2025 | Otezla, Otezla |
| Lilly USA, LLC | $208.34 | 2021-2025 | Taltz, Ebglyss |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $203.63 | 2022 | |
| Vyne Pharmaceuticals INC. | $190.07 | 2021 | |
| Ucb, INC. | $173.43 | 2021-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $161.59 | 2022-2025 | |
| Epi Health, LLC | $138.24 | 2021-2022 | |
| Acelrx Pharmaceuticals, INC. | $135.55 | 2021 | |
| Merz North America, INC. | $134.91 | 2022 | |
| Almirall LLC | $116.25 | 2021-2024 | Seysara |
| Biofrontera INC. | $95.12 | 2021-2025 | Ameluz, Rhodoled Xl, Bf-Rhodoled |
| Organogenesis INC. | $68.82 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.86 | 2022-2023 | Spevigo |
| Pfizer INC. | $56.67 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $30.07 | 2022-2023 | Valchlor |
| Genentech USA, INC. | $25.39 | 2024 | Xolair |
| Convatec INC. | $22.11 | 2024 | |
| Botanix Sb INC | $17.77 | 2025 | Sofdra |
| Tempus Ai, INC | $16.33 | 2024 | Merlin Test |
| Sebela Pharmaceuticals INC. | $16.01 | 2023 | Naftin, Pramosone |
| Lnhc, INC | $14.72 | 2025 | Zelsuvmi |
| Misonix INC | $13.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Bernhardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.